Yongjie Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yongjie Xie has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Jihui Hao
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, China
34 shared publications - Jing Liu
Fudan University Shanghai Cancer Center 1 Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai Shanghai, China
33 shared publications - Ziyun Liu
Tianjin Medical University Cancer Institute and Hospital 1 Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer Tianjin, People’s Republic of China
33 shared publications - Xupeng Hou
Department of Pancreatic Cancer, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, P.R. China
28 shared publications - Hongxia Sun
State Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
27 shared publications - Lin Li
Tianjin Medical University Cancer Institute and Hospital 3 Department of Pancreatic Cancer National Clinical Research Center for Cancer, Tianjin, China
27 shared publications
Latest Publications
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Albumin-bound paclitaxel–induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy for which neoadjuvant chemotherapy with albumin-bound paclitaxel combined with gemcitabine (AG) is a standard first-line approach for borderline resectable and locally advanced disease. However, secondary resistance to this regimen is common, and its underlying mechanisms remain poorly defined. In this study, we investigated how neoadjuvant AG therapy shapes the tumor stroma in PDAC. Single-cell transcriptomics of patient tumors revealed that AG treatment induces a phenotypic switch of cancer-associated fibroblasts (CAFs) from myofibroblastic (myCAF) to inflammatory (iCAF) states and identified a previously unrecognized TMEM100 + CAF subset enriched in nonresponders. Mechanistic studies showed that albumin-bound paclitaxel activates IL-2–STAT5 signaling to drive TMEM100 expression and that TMEM100 + CAFs promote chemoresistance through paracrine secretion of amphiregulin (AREG) and activation of tumor EGFR signaling. Genetic ablation of TMEM100 + CAFs in mouse models reversed CAF switching and enhanced the antitumor efficacy of AG therapy. These findings map chemotherapy-induced CAF plasticity, reveal a TMEM100-AREG axis of resistance, and highlight TMEM100 + CAFs as a promising target to sensitize PDAC to neoadjuvant treatment.
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Albumin-bound paclitaxel–induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy for which neoadjuvant chemotherapy with albumin-bound paclitaxel combined with gemcitabine (AG) is a standard first-line approach for borderline resectable and locally advanced disease. However, secondary resistance to this regimen is common, and its underlying mechanisms remain poorly defined. In this study, we investigated how neoadjuvant AG therapy shapes the tumor stroma in PDAC. Single-cell transcriptomics of patient tumors revealed that AG treatment induces a phenotypic switch of cancer-associated fibroblasts (CAFs) from myofibroblastic (myCAF) to inflammatory (iCAF) states and identified a previously unrecognized TMEM100 + CAF subset enriched in nonresponders. Mechanistic studies showed that albumin-bound paclitaxel activates IL-2–STAT5 signaling to drive TMEM100 expression and that TMEM100 + CAFs promote chemoresistance through paracrine secretion of amphiregulin (AREG) and activation of tumor EGFR signaling. Genetic ablation of TMEM100 + CAFs in mouse models reversed CAF switching and enhanced the antitumor efficacy of AG therapy. These findings map chemotherapy-induced CAF plasticity, reveal a TMEM100-AREG axis of resistance, and highlight TMEM100 + CAFs as a promising target to sensitize PDAC to neoadjuvant treatment.
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF23
Single-Cell and Spatial Transcriptomics Reveal CHCHD3 as a Therapeutic Target to Activate cGAS–STING and Overcome Immunosuppression in Lung Adenocarcinoma
A substantial proportion of patients with treatment-naïve lung adenocarcinoma (LUAD) exhibit intrinsic resistance to neoadjuvant chemoimmunotherapy, highlighting the need for mechanism-driven therapeutic strategies. In this study, we performed integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on clinical specimens from the CheckMate 816 trial to define the tumor immune microenvironment (TIME) dynamics associated with therapy resistance. The scRNA-seq data revealed distinct TIME features in nonresponders to neoadjuvant chemoimmunotherapy, characterized by the upregulation of CHCHD3. Mechanistically, CHCHD3 acted as a negative regulator of innate immunity by sequestering cGAS in mitochondria. This interaction between the CHCHD3 domain and the cGAS catalytic core reduced the cytosolic cGAS pool, thereby blunting STING-dependent signaling. Consequently, CHCHD3 knockout restored CXCL5/CXCL1 production, reduced M2-like tumor-associated macrophages, and promoted CD8+ T-cell infiltration. Integrated virtual and functional drug screening identified TN4510 as a small molecule that disrupts the CHCHD3–cGAS interface. TN4510 treatment effectively restored STING signaling and synergized with chemoimmunotherapy to suppress tumor growth in preclinical models. Together, these findings reveal that CHCHD3 drives chemoimmunotherapy resistance by sequestering cGAS to limit STING activation. Targeting CHCHD3 with TN4510 restores antitumor immunity, offering a translatable strategy to overcome treatment resistance in LUAD. Significance: Targeting CHCHD3 activates cGAS-STING signaling to stimulate anti-tumor immunity and sensitize lung cancer to chemoimmunotherapy, highlighting the therapeutic potential of this approach to improve patient outcomes.
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF23
Single-Cell and Spatial Transcriptomics Reveal CHCHD3 as a Therapeutic Target to Activate cGAS–STING and Overcome Immunosuppression in Lung Adenocarcinoma
A substantial proportion of patients with treatment-naïve lung adenocarcinoma (LUAD) exhibit intrinsic resistance to neoadjuvant chemoimmunotherapy, highlighting the need for mechanism-driven therapeutic strategies. In this study, we performed integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on clinical specimens from the CheckMate 816 trial to define the tumor immune microenvironment (TIME) dynamics associated with therapy resistance. The scRNA-seq data revealed distinct TIME features in nonresponders to neoadjuvant chemoimmunotherapy, characterized by the upregulation of CHCHD3. Mechanistically, CHCHD3 acted as a negative regulator of innate immunity by sequestering cGAS in mitochondria. This interaction between the CHCHD3 domain and the cGAS catalytic core reduced the cytosolic cGAS pool, thereby blunting STING-dependent signaling. Consequently, CHCHD3 knockout restored CXCL5/CXCL1 production, reduced M2-like tumor-associated macrophages, and promoted CD8+ T-cell infiltration. Integrated virtual and functional drug screening identified TN4510 as a small molecule that disrupts the CHCHD3–cGAS interface. TN4510 treatment effectively restored STING signaling and synergized with chemoimmunotherapy to suppress tumor growth in preclinical models. Together, these findings reveal that CHCHD3 drives chemoimmunotherapy resistance by sequestering cGAS to limit STING activation. Targeting CHCHD3 with TN4510 restores antitumor immunity, offering a translatable strategy to overcome treatment resistance in LUAD. Significance: Targeting CHCHD3 activates cGAS-STING signaling to stimulate anti-tumor immunity and sensitize lung cancer to chemoimmunotherapy, highlighting the therapeutic potential of this approach to improve patient outcomes.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure1-24 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Fig.S1. Analysis of the number of positive LNs and the lymph node ratio (LNR, the ratio of positive to examined nodes) in PDAC patients; Fig.S2. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S3. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S4. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S5. Validation of SPiDER probe and the effects of dasatinib plus quercetin; Fig.S6. The gating strategy for senescent cells and the senescence levels in normal tissues, IPMN and PDAC; Fig.S7. The effects of specific deletion of p16 and p21 in CAFs; Fig.S8.The effects of conditional deletion of p16 and p21 in CAFs; Fig.S9. Clinical significance of senescent CAFs in PDAC; Fig.S10. The paracrine effects of malignant epithelial components on the induction of senescent CAFs; Fig.S11. The validation of senescent CAFs; Fig.S12. The glucose metabolism level in senescent CAFs; Fig.S13. The effects of LDHA inhibition in LNM; Fig.S14. The effects of specific deletion of PHGDH in lymphatic endothelia cells. Data related to Fig.4P-R; Fig.S15. The evaluation of different lactylated histones in CAFs; Fig.S16. The distance between CAFs and Tregs in human and mouse models. Data related to Figure 6; Fig.S17. SenCAFs-derived lactate activates transcription of CCL17 by enhancing histone lactylation in LECs; Fig.S18. The HDAC inhibitor chidamide selectively kills senCAFs in PDAC; Fig.S19. The HDAC inhibitor chidamide selectively kills senCAFs, increases the efficacy of pancreatic cancer standard of care and further suppresses LNM and distal metastasis in PDAC;Fig.S20. The HDAC inhibitor chidamide could sensitize PDAC to chemoimmunotherapy;Fig.S21. The tumor re-challenge assay for chidamide plus chemoimmunotherapy; Fig.S22. The effects of chidamide in Pdgfrα-cre-p16/cdkn1aΔ and WT mice;Fig.S23. The therapeutic effects of gemcitabine, nab-paclitaxel, chidamide and QL1706 in PDX models;Fig.S24. Schematic illustration for the project.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure1-24 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Fig.S1. Analysis of the number of positive LNs and the lymph node ratio (LNR, the ratio of positive to examined nodes) in PDAC patients; Fig.S2. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S3. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S4. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S5. Validation of SPiDER probe and the effects of dasatinib plus quercetin; Fig.S6. The gating strategy for senescent cells and the senescence levels in normal tissues, IPMN and PDAC; Fig.S7. The effects of specific deletion of p16 and p21 in CAFs; Fig.S8.The effects of conditional deletion of p16 and p21 in CAFs; Fig.S9. Clinical significance of senescent CAFs in PDAC; Fig.S10. The paracrine effects of malignant epithelial components on the induction of senescent CAFs; Fig.S11. The validation of senescent CAFs; Fig.S12. The glucose metabolism level in senescent CAFs; Fig.S13. The effects of LDHA inhibition in LNM; Fig.S14. The effects of specific deletion of PHGDH in lymphatic endothelia cells. Data related to Fig.4P-R; Fig.S15. The evaluation of different lactylated histones in CAFs; Fig.S16. The distance between CAFs and Tregs in human and mouse models. Data related to Figure 6; Fig.S17. SenCAFs-derived lactate activates transcription of CCL17 by enhancing histone lactylation in LECs; Fig.S18. The HDAC inhibitor chidamide selectively kills senCAFs in PDAC; Fig.S19. The HDAC inhibitor chidamide selectively kills senCAFs, increases the efficacy of pancreatic cancer standard of care and further suppresses LNM and distal metastasis in PDAC;Fig.S20. The HDAC inhibitor chidamide could sensitize PDAC to chemoimmunotherapy;Fig.S21. The tumor re-challenge assay for chidamide plus chemoimmunotherapy; Fig.S22. The effects of chidamide in Pdgfrα-cre-p16/cdkn1aΔ and WT mice;Fig.S23. The therapeutic effects of gemcitabine, nab-paclitaxel, chidamide and QL1706 in PDX models;Fig.S24. Schematic illustration for the project.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2-3 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 2 shows the patient characteristics in the proof-of-concept clinical trial; Supplementary Table 3 shows treatment-related adverse events in the proof-of-concept clinical trial.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2-3 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 2 shows the patient characteristics in the proof-of-concept clinical trial; Supplementary Table 3 shows treatment-related adverse events in the proof-of-concept clinical trial.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table1 shows the senescence genesets
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table1 shows the senescence genesets
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Detailed Supplementary Methods 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Detailed Supplementary Methods and Materials
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessDetailed Supplementary Methods 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Detailed Supplementary Methods and Materials
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 4 shows primers and probes used in experiments.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 4 shows primers and probes used in experiments.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF23
Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Lymph node (LN) metastasis (LNM) in early-stage pancreatic ductal adenocarcinoma (PDAC) predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. In this study, we demonstrated that senescent cancer-associated fibroblasts (senCAF) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ regulatory T cells from the draining LNs accumulated around lymphatic vessels, which established an immunosuppressive perilymphatic niche. High-throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression, and improved chemoimmunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti–PD-1/CTLA-4) in patients with metastatic PDAC and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemoimmunotherapy efficacy. Significance: Our findings have revealed a closed link between cellular senescence, metabolic reprograming, and spatial immunosuppressive niche and PDAC metastasis, offering the potential senolytic drugs to improve chemoimmunotherapy efficacy in patients with PDAC.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF23
Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Lymph node (LN) metastasis (LNM) in early-stage pancreatic ductal adenocarcinoma (PDAC) predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. In this study, we demonstrated that senescent cancer-associated fibroblasts (senCAF) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ regulatory T cells from the draining LNs accumulated around lymphatic vessels, which established an immunosuppressive perilymphatic niche. High-throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression, and improved chemoimmunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti–PD-1/CTLA-4) in patients with metastatic PDAC and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemoimmunotherapy efficacy. Significance: Our findings have revealed a closed link between cellular senescence, metabolic reprograming, and spatial immunosuppressive niche and PDAC metastasis, offering the potential senolytic drugs to improve chemoimmunotherapy efficacy in patients with PDAC.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Splenic immunoglobulin-secreting cells quantified by ELISpot
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Splenic immunoglobulin-secreting cells quantified by ELISpot
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Lactate mediates SDC1/ENO1-induced regulation of stemness, immune evasion, and radioresistance
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Lactate mediates SDC1/ENO1-induced regulation of stemness, immune evasion, and radioresistance